Introduction: Gastrointestinal (GI) disorders benefit from direct treatment access to the GI tract (GIT). RNA molecules show therapeutic promise but are vulnerable to degradation in the GIT. Our study explores lipid nanoparticles (LNPs), usually given parenterally, for local RNA delivery, overcoming environmental challenges and delivery needs.
Learning Objectives:
At the completion of this activity, participants will know
Describes the formulation development rationale to deliver nucleic acids orally.
Demonstrates the use of biomimetic GI media to test both stability and efficacy of the formulation.
Discusses the importance and limitations of animal models.
